Polycystic Ovarian Syndrome - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Polycystic Ovarian Syndrome - Pipeline Review, H1 2016', provides an overview of the Polycystic Ovarian Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome - The report reviews pipeline therapeutics for Polycystic Ovarian Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Polycystic Ovarian Syndrome therapeutics and enlists all their major and minor projects - The report assesses Polycystic Ovarian Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Polycystic Ovarian Syndrome Overview 7 Therapeutics Development 8 Pipeline Products for Polycystic Ovarian Syndrome - Overview 8 Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis 9 Polycystic Ovarian Syndrome - Therapeutics under Development by Companies 10 Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes 11 Polycystic Ovarian Syndrome - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Polycystic Ovarian Syndrome - Products under Development by Companies 15 Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes 16 Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development 17 Addex Therapeutics Ltd 17 Crinetics Pharmaceuticals, Inc. 18 EffRx Pharmaceuticals S.A. 19 Euroscreen S.A. 20 Merck KGaA 21 Vicore Pharma AB 22 Polycystic Ovarian Syndrome - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 C-21 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 choriogonadotropin alfa - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ESN-364 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 JDSCR-004 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 KDT-501 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 metformin hydrochloride - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 MLE-4901 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Polycystic Ovarian Syndrome - Recent Pipeline Updates 45 Polycystic Ovarian Syndrome - Dormant Projects 47 Polycystic Ovarian Syndrome - Discontinued Products 48 Polycystic Ovarian Syndrome - Product Development Milestones 49 Featured News & Press Releases 49 Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients 49 Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364 49 Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 50 Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 50 Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 51 Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Pediatric Populations 51 Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2016 8 Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H1 2016 17 Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016 18 Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H1 2016 19 Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H1 2016 20 Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H1 2016 21 Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Polycystic Ovarian Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 45 Polycystic Ovarian Syndrome - Dormant Projects, H1 2016 47 Polycystic Ovarian Syndrome - Discontinued Products, H1 2016 48
List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2016 8 Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Targets, H1 2016 24 Number of Products by Stage and Targets, H1 2016 24 Number of Products by Mechanism of Actions, H1 2016 26 Number of Products by Stage and Mechanism of Actions, H1 2016 26 Number of Products by Routes of Administration, H1 2016 28 Number of Products by Stage and Routes of Administration, H1 2016 28 Number of Products by Molecule Types, H1 2016 30 Number of Products by Stage and Molecule Types, H1 2016 30
Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certainRead More...
Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers isRead More...
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.